<DOC>
	<DOCNO>NCT00002390</DOCNO>
	<brief_summary>The purpose study see give 1592U89 HIV-infected patient safe effective lower viral load ( level HIV blood ) raise level CD4 cell ( cell body help fight infection ) .</brief_summary>
	<brief_title>A Study Safety Effectiveness Different Doses 1592U89 HIV-Infected Patients</brief_title>
	<detailed_description>Patients randomize receive one three dose 1592U89 . During randomized dose phase , patient meet one follow criterion , he/she offer open-label 1592U89 ( 300 mg ) plus zidovudine ( ZDV ) plus lamivudine ( 3TC ) ( license antiretrovirals accord standard practice ) . Criteria base fall CD4 count ( return baseline two occasion least 1 month apart ) , disease progression ( define occurrence new AIDS-defining event accord CDC classification exclude CD4 count less 200 cells/mm3 ) , lack virus suppression ( define less 0.7log10 reduction viral load Week 4 repeat value 1 week later , 5000 copies/ml HIV RNA Weeks 12 , 16 , 20 , 24 , 5000 copies/ml anytime Week 24 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<criteria />
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
</DOC>